TP53 and breast carcinoma: In particular, we observed a significant modulation of some TAS2Rs in poor-prognosis AML groups, TP53-mut and TET2-mut patients, in line with the observed TAS2R level decrease in breast cancer cells with a more aggressive phenotype (18).